Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity

J Exp Med. 1996 Jan 1;183(1):283-7. doi: 10.1084/jem.183.1.283.

Abstract

Cytotoxic T lymphocytes (CTLs) are a critical component of the immune response to tumors. Tumor-derived peptide antigens targeted by CTLs are being defined for several human tumors and are potential immunogens for the induction of specific antitumor immunity. Dendritic cells (DC) are potent antigen-presenting cells (APCs) capable of priming CTL responses in vivo. Here we show that major histocompatibility complex class I-presented peptide antigen pulsed onto dendritic APCs induces protective immunity to lethal challenge by a tumor transfected with the antigen gene. The immunity is antigen specific, requiring expression of the antigen gene by the tumor target, and is eliminated by in vivo depletion of CD8+ T cells. Furthermore, mice that have rejected the transfected tumor are protected from subsequent challenge with the untransfected parent tumor. These results suggest that immunization strategies using antigen-pulsed DC may be useful for inducing tumor-specific immune responses.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Amino Acid Sequence
  • Animals
  • Antigen Presentation*
  • Cytotoxicity, Immunologic
  • Dendritic Cells / immunology*
  • Female
  • Immunization*
  • Melanoma, Experimental / therapy
  • Mice
  • Mice, Inbred BALB C
  • Molecular Sequence Data
  • Neoplasms, Experimental / therapy*
  • Peptide Fragments / therapeutic use*
  • Survival Analysis
  • Thymoma / therapy

Substances

  • Peptide Fragments